Conflict of interest H.C. Korting has previously collaborated with Novartis in the development of topicals containing terbinafine, and with Galderma concerning amorolfin-containing preparations. Drs’. P. Mayser, R. Shouey, A. Gupta and B. Sigurgeirsson have no conflict of interests. S. Hugot, M. Notter, K. Thangavelu, A. Parneix-Spake and J. Nyirady are employees of Novartis. Drs’ B.E. Elewski, P. Rich and M. Ling have received research grant fund from Novartis for the performing of the study. Dr B. Damaj is an employee of NexMed (USA), Inc. Dr D. Baker was a principal investigator at one of the research sites. Dr M. Ghannoum has accepted as a consultant for Novartis Pharmaceuticals.
Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs
Article first published online: 20 DEC 2011
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 3, pages 287–294, March 2013
How to Cite
Elewski, B.E., Ghannoum, M.A., Mayser, P., Gupta, A.K., Korting, H.-C., Shouey, R.J., Baker, D.R., Rich, P.A., Ling, M., Hugot, S., Damaj, B., Nyirady, J., Thangavelu, K., Notter, M., Parneix-Spake, A. and Sigurgeirsson, B. (2013), Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. Journal of the European Academy of Dermatology and Venereology, 27: 287–294. doi: 10.1111/j.1468-3083.2011.04373.x
Funding sources Novartis Pharma AG, Basel, Switzerland.
- Issue published online: 18 FEB 2013
- Article first published online: 20 DEC 2011
- Received: 29 May 2011; Accepted: 10 November 2011
Background Terbinafine nail solution (TNS) was developed for the treatment of onychomycosis.
Objective To assess the efficacy of TNS vs. vehicle and amorolfine 5% nail lacquer.
Methods Subjects with mild-to-moderate toe onychomycosis (25% to ≤75% nail-involvement, matrix uninvolved) were randomized to receive either TNS or vehicle in two double-blind studies, and to TNS or amorolfine in an active-controlled, open-label study. Primary endpoint was complete cure (no residual clinical involvement and negative mycology) at week 52. Secondary endpoints were mycological cure (negative mycology defined as negative KOH microscopy and negative culture) and clinical effectiveness (≤10% residual-involvement and negative mycology) at week 52.
Results Complete cure was not different between TNS vs. vehicle and amorolfine. Mycological cure was higher with TNS vs. vehicle, as was clinical effectiveness with TNS vs. vehicle, and TNS and amorolfine were not different for secondary efficacy endpoints. Patients achieving mycological cure had a better clinical outcome, and efficacy was improved in subjects with milder disease. Post hoc analysis suggests that nail thickness is an important prognostic factor. Moreover, mycological cure may require 6 months of treatment regimen while complete cure and clinical effectiveness may be achievable only after 10 months. A simulation study suggests that longer treatment duration would have resulted in higher complete cure with TNS vs. vehicle. Study treatments were well-tolerated.
Conclusion Primary efficacy objectives were not met in the studies reported herein. Possible reasons for failure to achieve significant outcomes include insufficient length of treatment; stringency of primary endpoint and severity of nail involvement of study population.